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Intermediate risk disease
Pathological status: PSA 10–20 ng/mL, or biopsy Gleason
score 7, or clinical stage T2b or T2c
Clinical note: Heterogeneous group with a wide inci-
dence of biochemical relapse & numerous curative therapy
options.
Problems with categorization: Detection of unfavourable
subgroup includes Gleason ≥4+3 and/or >50% positive
biopsies and/or >1 intermediate risk factors [1,2]
Role of MRI in practice:
1. If initial active surveillance is considered, then it is
important not to underestimate tumor grade/
volume/stage
2. For external beam radiotherapy, the presence of
unfavourable disease affects duration of adjuvant
hormonal therapy.
3. For focal therapy, index lesion localization is
needed
4. For surgery, accurate staging to enable curative
treatment with negative margins & nerve sparing if
possible
Type of MRI [3]:
• Lesion detection and localisation protocol with
T2W, DW-MRI and DCE-MRI ± MRSI for low
ADC lesions to assess aggressiveness
• Staging with multi-planar T2W, DW-MRI ± DCE-
MRI for ECE/SVI
High risk disease
Pathological status: PSA >20 ng/mL, or Gleason score
8–10, or clinical stage >T2c
Clinical note: Highest risk of biochemical recurrence
and cancer specific mortality but substantial population
heterogeneity
Prognostic subgroups [4]:
■ Good prognosis subgroup: one single risk factor
(any)
■ Intermediate prognosis subgroup: two risk factors
(PSA >20 ng/ml and stage cT3–4); No Gleason 8+
disease
■ Poor prognosis subgroup: GS >7 and stage cT3–4
and/or PSA >20 ng/ml
Clinical sub-groups: localized, locally advanced &
metastatic
Problems with categorization: Local staging accuracy &
the detection of metastatic disease
Role of MRI in practice
1. local and nodal staging: to detect extensive ECE/
SVI that would preclude radical surgery with negative
margins. Nerve sparing rarely undertaken.
2. To detect nodal and bone metastases
Type of MRI [3,5]:
• Accurate local staging and pelvic nodal
assessments
• Bone scan + CT abdomen or WB-MRI
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